Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells

Authors: Geetanjali Kharmate, Padmesh S Rajput, Yu-Chen Lin, Ujendra Kumar

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Somatostatin receptors (SSTRs) and opioid receptors (ORs) belong to the superfamily of G-protein coupled receptors and function as negative regulators of cell proliferation in breast cancer. In the present study, we determined the changes in SSTR subtype 2 (SSTR2) and μ, δ and κ-ORs expression, signaling cascades and apoptosis in three different breast cancer cells namely MCF-7, MDA-MB231 and T47D.

Methods

Immunocytochemistry and western blot analysis were employed to study the colocalization and changes in MAPKs (ERK1/2 and p38), cell survival pathway (PI3K/AKT) and tumor suppressor proteins (PTEN and p53) in breast cancer cell lines. The nature of cell death upon activation of SSTR2 or OR was analysed using flow cytometry analysis.

Results

The activation of SSTR2 and ORs modulate MAPKs (ERK1/2 and p38) in cell dependent and possibly estrogen receptor (ER) dependent manner. The activation of tumor suppressor proteins phosphatase and tensin homolog (PTEN) and p53 antagonized the PI3K/AKT cell survival pathway. Flow cytometry analyses reveal increased necrosis as opposed to apoptosis in MCF-7 and T47D cells when compared to ER negative MDA-MB231 cells. Furthermore, receptor and agonist dependent expression of ORs in SSTR2 immunoprecipitate suggest that SSTR2 and ORs might interact as heterodimers and inhibit epidermal growth factor receptor phosphorylation.

Conclusion

Taken together, findings indicate a new role for SSTR2/ORs in modulation of signaling pathways involved in cancer progression and provide novel therapeutic approaches in breast cancer treatment.
Appendix
Available only for authorised users
Literature
1.
2.
Buscail L, Esteve J, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll A, Bell GI, Schally AV, Vaysse N, Susini C: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Nat Acad Sci. 1995, 92 (5): 1580-1584. 10.1073/pnas.92.5.1580.PubMedCentralCrossRefPubMed
3.
Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C: Regulation of cell proliferation by somatostatin. Ann Endocrinol (Paris). 2002, 63 (2 Pt 3): 2S13-12S18.
4.
Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S: Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat. 2005, 92 (2): 175-186. 10.1007/s10549-005-2414-0.CrossRefPubMed
5.
Prevost G, Hosford D, Thomas F: Receptors for somatostatin and somatostatin analogues in human breast tumors. Ann N Y Acad Sci. 1994, 733: 147-154. 10.1111/j.1749-6632.1994.tb17264.x.CrossRefPubMed
6.
Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S: Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004, 114 (3): 349-356.PubMedCentralCrossRefPubMed
7.
Boccardo F, Amoroso D: Management of breast cancer: is there a role for somatostatin and its analogs?. Chemotherapy. 2001, 47 (Suppl. 2): 62-77. 10.1159/000049162.CrossRefPubMed
8.
Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res. 1993, 55 (4): 446-450. 10.1006/jsre.1993.1167.CrossRefPubMed
9.
Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G: Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003, 144 (4): 1574-1584. 10.1210/en.2002-220949.CrossRefPubMed
10.
Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G, Schettini G: Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol. 1999, 141 (4): 396-408. 10.1530/eje.0.1410396.CrossRefPubMed
11.
Liu AMF, Wong YH: Activation of nuclear factor ΰB by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves GÎ ± 14 and multiple signaling components. J Biol Chem. 2005, 280 (41): 34617-34625. 10.1074/jbc.M504264200.CrossRefPubMed
12.
Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J: Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to egf receptors. Intnl J Can. 1990, 46 (3): 416-420. 10.1002/ijc.2910460315.CrossRef
13.
Watt HL, Kharmate GD, Kumar U: Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal. 2009, 21 (3): 428-439. 10.1016/j.cellsig.2008.11.012.CrossRefPubMed
14.
Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S: Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab. 1995, 80 (10): 2974-2979. 10.1210/jc.80.10.2974.PubMed
15.
Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S: Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem. 2002, 277 (22): 19762-19772. 10.1074/jbc.M110373200.CrossRefPubMed
16.
He Y, Yuan X-m, Lei P, Wu S, Xing W, Lan X-l, Zhu H-f, Huang T, Wang G-b, An R: The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin. 2009, 30 (7): 1053-1059. 10.1038/aps.2009.59.PubMedCentralCrossRefPubMed
17.
Bousquet C, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, Fanjul M, Ferrand A, Fourmy D, Pichereaux C, Monsarrat B: Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. Embo J. 2006, 25 (17): 3943-3954. 10.1038/sj.emboj.7601279.PubMedCentralCrossRefPubMed
18.
Grant M, Kumar U: The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept. 2009, 159 (1–3): 3-8.
19.
Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW: Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol. 1997, 11 (8): 1062-1069. 10.1210/me.11.8.1062.CrossRefPubMed
20.
Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U: Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochim Biophys Acta. 2011, 1813 (6): 1172-1189. 10.1016/j.bbamcr.2011.03.006.CrossRefPubMed
21.
Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U: Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology. 2011, 152 (3): 931-945. 10.1210/en.2010-0940.CrossRefPubMed
22.
Foekens JA, Portengen H, van Putten WLJ, Trapman A, Reubi JC, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989, 49: 7002-7009.PubMed
23.
Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997, 410 (1): 83-86. 10.1016/S0014-5793(97)00412-2.CrossRefPubMed
24.
Bacus SS, Gudkov AV, Esteva FJ, Yarden Y: Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Dis. 2000, 11: 63-75.PubMed
25.
Hatzoglou A, Ouafik LH, Bakogeorgou E, Thermos K, Castanas E: Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res. 1995, 55 (23): 5632-5636.PubMed
26.
Reisine T, Bell GI: Molecular biology of opioid receptors. Trends Neurosci. 1993, 16 (12): 506-510. 10.1016/0166-2236(93)90194-Q.CrossRefPubMed
27.
Panagiotou S, Bakogeorgou E, Papakonstanti E, Hatzoglou A, Wallet F, Dussert C, Stournaras C, Martin P-M, Castanas E: Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: involvement of cytoskeletal elements. J Cell Biochem. 1999, 73 (2): 204-211. 10.1002/(SICI)1097-4644(19990501)73:2<204::AID-JCB6>3.0.CO;2-V.CrossRefPubMed
28.
Persson AI, Thorlin T, Bull C, Zarnegar P, Ekman R, Terenius L, Eriksson PS: Mu- and delta-opioid receptor antagonists decrease proliferation and increase neurogenesis in cultures of rat adult hippocampal progenitors. Eur J Neurosci. 2003, 17 (6): 1159-1172. 10.1046/j.1460-9568.2003.02538.x.CrossRefPubMed
29.
Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE: Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst. 1987, 79 (5): 1059-1065.PubMed
30.
Scopsi L, Balslev E, Brunner N, Poulsen HS, Andersen J, Rank F, Larsson LI: Immunoreactive opioid peptides in human breast cancer. Am J Pathol. 1989, 134 (2): 473-479.PubMedCentralPubMed
31.
Hatzoglou A, Bakogeorgou E, Castanas E: The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol. 1996, 296 (2): 199-207. 10.1016/0014-2999(95)00703-2.CrossRefPubMed
32.
Maneckjee R, Biswas R, Vonderhaar BK: Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res. 1990, 50 (8): 2234-2238.PubMed
33.
Devi LA: Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci. 2001, 22 (10): 532-537. 10.1016/S0165-6147(00)01799-5.CrossRefPubMed
34.
Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000, 288 (5463): 154-157. 10.1126/science.288.5463.154.CrossRefPubMed
35.
Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U: Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2: co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal. 2007, 19 (11): 2304-2316. 10.1016/j.cellsig.2007.07.007.CrossRefPubMed
36.
Grant M, Collier B, Kumar U: Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem. 2004, 279 (35): 36179-36183. 10.1074/jbc.M407310200.CrossRefPubMed
37.
Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E: Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA. 2002, 99 (5): 3294-3299. 10.1073/pnas.042705099.PubMedCentralCrossRefPubMed
38.
Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005, 153 (1): 135-141. 10.1530/eje.1.01950.CrossRefPubMed
39.
Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P: Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology. 2006, 83 (3–4): 258-263.CrossRefPubMed
40.
Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P: Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary Somatotroph adenoma cells. J Clin Endocrinol Metab. 2002, 87 (12): 5545-5552. 10.1210/jc.2002-020934.CrossRefPubMed
41.
Rivera JA, Alturaihi H, Kumar U: Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J Carcinog. 2005, 4 (1): 10-10.1186/1477-3163-4-10.PubMedCentralCrossRefPubMed
42.
Xu Y, Berelowitz M, Bruno JF: Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology. 1995, 136 (11): 5070-5075. 10.1210/en.136.11.5070.PubMed
43.
Xu Y, Song J, Berelowitz M, Bruno JF: Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology. 1996, 137 (12): 5634-5640. 10.1210/en.137.12.5634.PubMed
44.
Kumar U: Expression of somatostatin receptor subtypes (SSTR1-5) in alzheimer’s disease brain: an immunohistochemical analysis. Neuroscience. 2005, 134: 525-538. 10.1016/j.neuroscience.2005.04.001.CrossRefPubMed
45.
Kumar U: Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J Comp Neurol. 2007, 504 (2): 185-205. 10.1002/cne.21444.CrossRefPubMed
46.
Enslen H, Brancho DM, Davis RJ: Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. Embo J. 2000, 19 (6): 1301-1311. 10.1093/emboj/19.6.1301.PubMedCentralCrossRefPubMed
47.
Zarubin T, Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005, 15 (1): 11-18. 10.1038/sj.cr.7290257.CrossRefPubMed
48.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007, 12 (4): 395-402. 10.1016/j.ccr.2007.08.030.CrossRefPubMed
49.
Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D: PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010, 177 (4): 1647-1656. 10.2353/ajpath.2010.090885.PubMedCentralCrossRefPubMed
50.
López-Knowles E, O’Toole SA, McNeil CM, Millar EKA, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL: PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2009, 126 (5): 1121-1131.
51.
Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V: Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Br Cancer Res. 2008, 10 (5): R80-10.1186/bcr2149.CrossRef
52.
Gomes I, Jordan BA, Gupta A, Rios C, Trapaidze N, Devi LA: G protein coupled receptor dimerization: implications in modulating receptor function. J Mol Med. 2001, 79 (5–6): 226-242.CrossRefPubMed
53.
Nebreda AR, Porras A: p38 MAP kinases: beyond the stress response. Trends Biochem Sci. 2000, 25 (6): 257-260. 10.1016/S0968-0004(00)01595-4.CrossRefPubMed
54.
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. J Biol Chem. 2001, 276 (13): 9817-9824. 10.1074/jbc.M010840200.CrossRefPubMed
55.
Sabbatini P, McCormick F: Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem. 1999, 274 (34): 24263-24269. 10.1074/jbc.274.34.24263.CrossRefPubMed
56.
Zheng L, Ren JQ, Li H, Kong ZL, Zhu HG: Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. Cell Res. 2004, 14 (6): 497-506. 10.1038/sj.cr.7290253.CrossRefPubMed
57.
Gan HK, Walker F, Burgess AW, Rigopoulos A, Scott AM, Johns TG: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive Untethered EGFR dimers. J Biol Chem. 2007, 282 (5): 2840-2850.CrossRefPubMed
58.
Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol. 1987, 1 (3): 216-223. 10.1210/mend-1-3-216.CrossRefPubMed
59.
Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 2001, 61 (15): 5790-5795.PubMed
60.
Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ: Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res. 2009, 69 (6): 2191-2194. 10.1158/0008-5472.CAN-08-1056.CrossRefPubMed
61.
Williams G, Ball J, Bloom S, Joplin GF: Improvement in headache associated with prolactinoma during treatment with a somatostatin analogue: an “N of 1” study. N Engl J Med. 1986, 315 (18): 1166-1167.CrossRefPubMed
Metadata
Title
Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells
Authors
Geetanjali Kharmate
Padmesh S Rajput
Yu-Chen Lin
Ujendra Kumar
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-93

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

Oncogenic transformation of mammary epithelial cells by transforming growth factor beta independent of mammary stem cell regulation

Primary research

TLR9 signaling repressed tumor suppressor miR-7 expression through up-regulation of HuR in human lung cancer cells

Review

The flavokawains: uprising medicinal chalcones

Primary research

Spindle and kinetochore associated complex subunit 1 regulates the proliferation of oral adenosquamous carcinoma CAL-27 cells in vitro

Primary research

Effect of DNA methylation inhibitor on RASSF1A genes expression in non-small cell lung cancer cell line A549 and A549DDP

Primary research

Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits